Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Concizumab (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms explorer7
- Sponsors Novo Nordisk
Most Recent Events
- 06 Jun 2025 According to Novo Nordisk media release, data from this trial will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25.
- 20 Dec 2024 According to Novo Nordisk media release, announced today that the U.S. Food and Drug Administration (FDA) approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors FDA approval is based on data from this trial.
- 03 Dec 2024 According to Novo Nordisk media release, company announced they will presenting data of this trial at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California.